Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Contexte
Composés actifs
Mécanisme d'action
Preuves cliniques
DIM shows potential in reducing the risk and treating various cancers, including breast, ovarian, gastrointestinal, and non-small-cell lung cancer, by targeting cell survival and proliferation [PMID:40841315, PMID:23140296, PMID:27447608, PMID:40100489].
In mouse models, DIM ameliorated smoking-induced inflammatory amplification, reduced synovial hyperplasia, and inhibited abnormal platelet activation [PMID:40349797, PMID:41076479].
DIM was shown to relieve visceral pain under colitis conditions in mice via the AhR/Nrf2/Arg-1-mediated arginine metabolism pathway [PMID:37216760].
DIM attenuated object recognition memory deficits induced by binge ethanol exposure in mice [PMID:41390010].
DIM demonstrated anti-biofilm activity against Acinetobacter baumannii and Pseudomonas aeruginosa in vitro [PMID:35631553].
Sécurité et effets indésirables
Interactions médicamenteuses
Synthèse des preuves
Sources PubMed
- 1.PMID: 36972159 (2023) — Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. · Annual review of food science and technology
- 2.PMID: 38796426 (2024) — Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. · Journal of nanobiotechnology
- 3.PMID: 23140296 (2012) — DIMming ovarian cancer growth. · Current drug targets
- 4.PMID: 40841315 (2025) — Cruciferous Vegetables, Bioactive Metabolites, and Microbiome for Breast Cancer Prevention. · Annual review of nutrition
- 5.PMID: 37216760 (2023) — 3, 3'-diindolylmethane enhances macrophage efferocytosis and subsequently relieves visceral pain via the AhR/Nrf2/Arg-1-mediated arginine metabolism pathway.